BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
270.10
-9.83 (-3.51%)
At close: Jun 5, 2026, 4:00 PM EDT
269.09
-1.01 (-0.38%)
After-hours: Jun 5, 2026, 7:57 PM EDT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 1.51B CNY in the quarter ending March 31, 2026, with 35.46% growth. This brings the company's revenue in the last twelve months to 5.74B, up 37.44% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of 5.34B with 40.23% growth.
Revenue (ttm)
5.74B CNY
Revenue Growth
+37.44%
P/S Ratio
5.26
Revenue / Employee
478,266 CNY
Employees
12,000
Market Cap
30.03B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Jazz Pharmaceuticals | 4.44B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
ONC News
- 4 days ago - Baker Bros. Advisors LP Significantly Reduces Stake in BeOne Medicines Ltd - GuruFocus
- 5 days ago - BeOne Medicines price target raised to $436 from $425 at RBC Capital - TheFly
- 5 days ago - BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - MarketBeat
- 5 days ago - BeOne Medicines AG Transcript: Study update - Transcripts
- 5 days ago - BeOne Medicines AG Press release: Study update - Filings
- 5 days ago - BeOne Medicines AG Slides: Study update - Filings
- 6 days ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters
- 6 days ago - BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 - Business Wire